FN2 Earnings Intelligence
Danaher Corporation earnings overview
Latest Danaher Corporation (DHR) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Danaher Corporation
Danaher delivered a Q2 beat with revenue of $6.3 billion (core growth +4.5% YoY) and adjusted EPS of $1.94, ahead of the $1.85 consensus estimate. The company raised full-year adjusted EPS guidance to $8.45–$8.60 from $8.35–$8.55. Despite these positives, shares fell approximately 11% on report day with 6.6x normal volume — the market focused on bioprocessing shipment timing delays that pressured near-term equipment revenue conversion, even though underlying order growth remained in the mid-teens. The Masimo acquisition closed in early June, earlier than expected, and is immediately accretive. New product launches across life sciences (Biacore 8S, SCIEX novus V55) and diagnostics (Access pTau217 Alzheimer's blood assay) broaden the growth base. The stock has since recovered most of the initial decline, trading at $199.08 as of July 28. With a bullish score of 82 and confident…
Danaher Corporation
Danaher's latest call provides evidence for a constructive operating trajectory: bioprocessing consumables and equipment orders were strong, EPS guidance increased, and management cited new products, AI-enabled processes, and Masimo synergies as growth levers. The counterevidence is modest core-revenue growth, revenue below consensus, and execution risks around equipment conversion, China, seasonality, costs, and integration.
Danaher Corporation
The latest analysis supports a constructive but conditional view: Danaher's bioprocessing demand, product launches and potential recovery in pharma R&D support its growth outlook, while China, funding and equipment-order risks limit confidence in the durability of that trajectory.
Danaher Corporation
The quarter supports a constructive but qualified view: resilient bioprocessing consumables demand, diagnostics growth, and productivity actions offset uneven equipment demand. The evidence is positive for growth, but China policy, funding conditions, and the durability of margin gains remain important tests.
Get the DHR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.